Publication date: Jul 18, 2019 ^A “The findings add to the growing body of evidence that inhibition of p38 alpha kinase has the potential to reverse synaptic dysfunction and treat ... Read more

Publication date: Jul 10, 2019 CAMBRIDGE, Massachusetts, July 9, 2019 /PRNewswire/ — EIP Pharma, Inc. , a CNS-focused therapeutics company, today announced the initiation of a new Phase 2 proof-of-concept ... Read more

Publication date: Jun 10, 2019 This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD). The primary objective is to determine whether ... Read more